We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 591

“Hide No Harm Act of 2015” targets employers, directors and officers
  • Barnes & Thornburg LLP
  • USA
  • November 5 2015

The 114th Congress has now taken up the policy recently announced by the Department of Justice (DOJ) through the Yates Memo. The Hide No Harm Act (S

EU political update: 23 27 June 2014
  • Clifford Chance LLP
  • China, European Union, USA
  • June 23 2014

On 19 June 2014, during the fourth Biennial High-Level Consumer Product Safety Trilateral Summit which was held in Brussels, officials of the

Even without knowledge or participation, corporate officers can be criminally liable for subordinates' misdeeds
  • Fox Rothschild LLP
  • USA
  • July 30 2012

The Food and Drug Administration and the U.S. Court of Appeals for the D.C. Circuit’s treatment of former Purdue Pharma executives is a reminder to executives and in-house counsel, particularly those in regulated industries, that they can face criminal liability and career-ending debarment for their company’s conduct, even if the executives did not personally participate in the conduct or even know about it

New indictment of in-house counsel indicates enhanced efforts to hold corporate executives accountable for food and drug law violations
  • Fish & Richardson PC
  • USA
  • November 15 2010

This year, both the Food and Drug Administration (FDA) and Department of Justice have repeatedly signaled to the pharmaceutical and medical device industries that they should expect an increase in the criminal prosecution of individuals for alleged violations of the food and drug laws, with the stated goals of increasing deterrence and greater compliance

GAO report calls for increase in FDA criminal prosecutions of company executives
  • Reed Smith LLP
  • USA
  • March 15 2010

The GAO recently issued a report entitled "Food and Drug Administration: Improved Monitoring and Development of Performance Measures Needed to Strengthen Oversight of Criminal and Misconduct Investigations," at the request of Senate Finance Committee Ranking Republican Charles Grassley

FDA to increase enforcement actions against corporate officials
  • Faegre Baker Daniels
  • USA
  • March 5 2010

Corporate executives have rarely been personal targets of FDA enforcement actions

Marc D. Powers
  • Baker & Hostetler LLP

Jonathan S. Feld
  • Dykema Gossett PLLC

Mark Anstoetter
  • Shook Hardy & Bacon LLP

Patrick Henderson
  • Shook Hardy & Bacon LLP